This review discusses pharmacology, dosage, adverse events and key trials. It also provides commentary and recommendations from Professor Miles Prince, Director of Molecular Oncology and Cancer Immunology at Epworth Healthcare and Director, Centre for Blood Cell Therapies at Peter MacCallum Cancer Centre and Associate Professor Judith Trotman, Director of the Concord Haematology Clinical Research Unit and Haematologist.
Please login below to download this issue (PDF)